Browse All

Current Filters

CLEAR FILTER x

TITLE

Long-term Efficacy of Satralizumab in Adults with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon

Author:Traboulsee, Anthony   Kleiter, Ingo   Palace, Jacqueline   Fujihara, Kazuo   Saiz, Albert   Vodopivec, Ivana   Klingelschmitt, Gaelle   Marcillat, Carole   Bennett, Jeffrey   

Session Name:S5: Autoimmune Neurology: NMOSD and MG, A Focus on Treatment Trials  

Topic:Autoimmune Neurology  

Program Number:S5.001  

Author Institution:University of British Columbia, Vancouver, BC, Canada  Ruhr University Bochum, Bochum, Germany  John Radcliffe Hospital, Oxford, United Kingdom  Fukushima Medical University School of Medicine, Fukushima, Japan  University of Barcelona, Barcelona, Spain  F. Hoffmann-La Roche Ltd, Basel, Switzerland  University of Colorado School of Medicine, Aurora, CO  

Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial

Author:Pittock, Sean   Barnett, Michael   Bennett, Jeffrey   Berthele, Achim   de Sèze, Jérôme   Levy, Michael   Nakashima, Ichiro   Oreja Guevara, Celia   Palace, Jacqueline   Paul, Friedemann   Pozzilli, Carlo   Allen, Kerstin   Mashhoon, Yasmin   Yountz, Marcus   Kim, Ho Jin   

Session Name:S5: Autoimmune Neurology: NMOSD and MG, A Focus on Treatment Trials  

Topic:Autoimmune Neurology  

Program Number:S5.002  

Author Institution:Department of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA, Rochester, MN  Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia  Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia, Camperdown, Australia  Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado, Aurora, CO, USA, Aurora, CO  Department of Neurology, School of Medicine, Technical University of Munich, Munich, Germany, Muenchen, Germany  Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, Strasbourg, France, Strasbourg, France  Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA  Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan  Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, Sendai, Japan  Department of Neurology, Hospital Clínico Universitario San Carlos, IdISCC, Madrid, Spain  Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain  Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK, Oxford, United Kingdom  Experimental and Clinical Research Center and NeuroCure Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany  Department of Human Neuroscience, University Sapienza, Rome, Italy, Rome, Italy  Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Boston, MA  Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Watertown, MA  Alexion, AstraZeneca Rare Disease, Boston, MA, USA *At the time this research was conducted., Needham, MA  Department of Neurology, National Cancer Center, Goyang, South Korea, Goyang, Korea, Republic of  

Efficacy subgroup analyses from the phase 3 CHAMPION-NMOSD trial in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

Author:Levy, Michael   Pittock, Sean   Barnett, Michael   Bennett, Jeffrey   Berthele, Achim   De Seze, Jerome   Nakashima, Ichiro   Oreja Guevara, Celia   Palace, Jacqueline   Paul, Friedemann   Pozzilli, Carlo   Allen, Kerstin   Mashhoon, Yasmin   Yountz, Marcus   Kim, Ho Jin   

Session Name:S5: Autoimmune Neurology: NMOSD and MG, A Focus on Treatment Trials  

Topic:Autoimmune Neurology  

Program Number:S5.003  

Author Institution:Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA  Department of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA, Rochester, MN  Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia  Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia, Camperdown, Australia  Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado, Aurora, CO, USA, Aurora, CO  Department of Neurology, School of Medicine, Technical University of Munich, Munich, Germany, Muenchen, Germany  Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, France, Strasbourg, France  Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan  Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, Sendai, Japan  Department of Neurology, Hospital Clínico Universitario San Carlos, IdISCC, Madrid, Spain  Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain  Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK, Oxford, United Kingdom  Experimental and Clinical Research Center and NeuroCure Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany  Department of Human Neuroscience, University Sapienza, Rome, Italy, Rome, Italy  Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Boston, MA  Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Watertown, MA  Alexion, AstraZeneca Rare Disease, Boston, MA, USA *At the time this research was conducted., Needham, MA  Department of Neurology, National Cancer Center, Goyang, South Korea, Goyang, Korea, Republic of  

Pharmacokinetics and Pharmacodynamics of Ravulizumab in Adults with Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder During the Phase 3 CHAMPION-NMOSD trial

Author:Ortiz, Stephan   Pittock, Sean   Berthele, Achim   Levy, Michael   Nakashima, Ichiro   Oreja Guevara, Celia   Kim, Ho Jin   

Session Name:S5: Autoimmune Neurology: NMOSD and MG, A Focus on Treatment Trials  

Topic:Autoimmune Neurology  

Program Number:S5.004  

Author Institution:Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Boston, MA  Department of Neurology, Center MS and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA, Rochester, MN  Department of Neurology, School of Medicine, Technical University Munich, Munich, Germany, Munich, Germany  Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA  Department of Neurology, Tohoku University Graduate School of Medicine  Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, Sendai, Japan  Department of Neurology, Hospital Clínico Universitario San Carlos  Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain  Department of Neurology, National Cancer Center, Goyang, South Korea , Goyang, Korea, Republic of  

Association of B cell Subsets and Aquaporin-4 antibody titers with Disease Activity in Participants in the N-MOmentum trial Receiving Inebilizumab Treatment

Author:Pittock, Sean   Paul, Friedemann   Kim, Ho Jin   Smith, Michael   Rees, William   Patterson, Kristina   Cree, Bruce   Bennett, Jeffrey   

Session Name:S5: Autoimmune Neurology: NMOSD and MG, A Focus on Treatment Trials  

Topic:Autoimmune Neurology  

Program Number:S5.005  

Author Institution:Mayo Clinic Dept of Neuro, Rochester, MN  Charite Universitatsmedizin in Berlin, Berlin, Germany  National Cancer Center, Goyang, Korea, Republic of  Horizon Therapeutics plc, Gaithersburg, MD  Horizon Therapeutics plc, Deerfield, IL  UCSF, Multiple Sclerosis Center, San Francisco, CA  University of Colorado School of Medicine, Aurora, CO